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Abstract
Background: Resident fibroblasts synthesize the cardiac extracellular matrix, and can undergo phenotype
conversion to myofibroblasts to augment matrix production, impairing function and contributing to organ failure.
A significant gap in our understanding of the transcriptional regulation of these processes exists. Given the key role
of this phenotype conversion in fibrotic disease, the identification of such novel transcriptional regulators may yield
new targets for therapies for fibrosis.
Results: Using explanted primary cardiac fibroblasts in gain- and loss-of-function studies, we found that scleraxis
critically controls cardiac fibroblast/myofibroblast phenotype by direct transcriptional regulation of myriad genes
that effectively define these cells, including extracellular matrix components and α-smooth muscle actin. Scleraxis
furthermore potentiated the TGFβ/Smad3 signaling pathway, a key regulator of myofibroblast conversion, by
facilitating transcription complex formation. While scleraxis promoted fibroblast to myofibroblast conversion, loss of
scleraxis attenuated myofibroblast function and gene expression. These results were confirmed in scleraxis knockout
mice, which were cardiac matrix-deficient and lost ~50 % of their complement of cardiac fibroblasts, with evidence
of impaired epithelial-to-mesenchymal transition (EMT). Scleraxis directly transactivated several EMT marker genes,
and was sufficient to induce mesenchymal/fibroblast phenotype conversion of A549 epithelial cells. Conversely, loss
of scleraxis attenuated TGFβ-induced EMT marker expression.
Conclusions: Our results demonstrate that scleraxis is a novel and potent regulator of cellular progression along
the continuum culminating in the cardiac myofibroblast phenotype. Scleraxis was both sufficient to drive
conversion, and required for full conversion to occur. Scleraxis fulfills this role by direct transcriptional regulation of
key target genes, and by facilitating TGFβ/Smad signaling. Given the key role of fibroblast to myofibroblast
conversion in fibrotic diseases in the heart and other tissue types, scleraxis may be an important target for
therapeutic development.
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Background
Resident cardiac fibroblasts (FBs) are active regulators of
myocardial function in health and disease, serving as a
source of autocrine and paracrine factors to support car-
diomyocyte function, as well as synthesizing the extracel-
lular matrix (ECM)—a highly dynamic structure necessary
for maintaining cardiac homeostasis, transmitting
contractile forces, preventing myocyte slippage and facili-
tating intercellular signaling [1]. Cardiomyocytes comprise
the bulk of the myocardial volume; however, intersti-
tial FBs are the most numerous cell type and coordin-
ate the maintenance of ECM through production and
secretion of structural proteins, growth factors, cyto-
kines and proteinases [2].
While FB activity is typically low in the healthy heart,
aging, stress, inflammation or damage can instigate a
phenotypic conversion to proto-myofibroblasts (pMFBs)
and myofibroblasts (MFBs), resulting in dramatic up-
regulation of ECM synthesis, particularly fibrillar colla-
gen types I and III [1, 3–6]. During this transition, FBs
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begin to express α-smooth muscle actin (αSMA/Acta2),
which is incorporated into newly formed contractile
bundles and stress fibers that impart cell contractility to
facilitate damage repair [7–9]. MFBs are further distin-
guished from their precursors by up-regulation of non-
muscle myosin heavy chain IIB (embryonic smooth
muscle myosin; SMemb/Myh10) and the extra domain-A
splice variant of fibronectin (EDA-Fn/Fn1) [3, 10, 11].
Production and secretion of factors involved in cell sig-
naling and adhesion, including proteoglycans and matri-
cellular proteins, also increase [12–14]. In the non-
stressed heart, MFBs are found at the cardiac valves,
playing a key role in valve maintenance [15]. Several in-
ducers of the FB to MFB conversion process have been
identified, including TGFβ; however, the underlying mo-
lecular mechanisms remain incompletely defined, and it
is unclear whether FB phenotype conversion is con-
trolled by a central factor [10, 16].
The basic helix-loop-helix transcription factor scler-
axis (Scx) is required for development and function
of ECM-rich tissues, including tendons and cardiac
valves [15, 17]. We have shown that Scx directly reg-
ulates Col1a2 gene expression in primary cardiac FBs
and MFBs, and is up-regulated in the cardiac infarct
scar or in response to TGFβ signaling [6, 18]. Scx
similarly controls expression of Col1a1 in tenocytes,
suggesting a direct role for this transcription factor in
modulating fibrillar collagen production across tissues
[19]. However, it is unknown whether Scx plays a
broader role in ECM synthesis or FB biology.
Here we report that Scx is a required and potent regu-
lator of the cardiac FB and MFB phenotype and attend-
ant gene expression, including the hallmarks of ECM
production and cell contraction. Ex vivo, Scx induced
the expression of various fibrillar collagens, proteogly-
cans, matrix metalloproteinases (MMPs) and numerous
markers of the FB and MFB phenotype in primary car-
diac pMFBs, and directly transactivated the gene pro-
moters of vimentin, MMP2 and fibronectin. Scx was
sufficient and necessary for the expression of αSMA via
direct promoter binding, inducing the incorporation of
αSMA into stress fibers and consequent cell contraction.
In contrast, Scx knockdown significantly attenuated the
expression of ECM and FB/MFB marker genes, and fully
attenuated TGFβ-mediated cell contraction. These find-
ings were recapitulated in vivo: the hearts of Scx knock-
out mice presented with dramatic losses of ECM mass
and expression of ECM and FB marker genes. The func-
tion of Scx null cardiac FBs could be rescued by restor-
ation of Scx expression. We found that Scx was required
for Smad3-mediated fibrillar collagen gene expression,
and the assembly of a Smad3-containing transcriptional
complex at the Col1a2 gene promoter. Surprisingly, Scx
null hearts exhibited a ~50 % reduction in FB number.
This effect may be due to a failure of epithelial precur-
sors to undergo mesenchymal transition during develop-
ment since Scx was found to regulate expression of
mesenchymal markers, including Twist1 and Snai1, lead-
ing to elevated epithelial and reduced mesenchymal
marker gene expression in Scx null hearts. Furthermore,
Scx expression in A549 epithelial cells reduced epithelial
markers while up-regulating mesenchymal and FB
markers, as well as fibrillar collagens. Together, these re-
sults reveal a novel and critical role for Scx in governing
the hallmarks of the cardiac FB phenotype, including the
regulation of mesenchymal character, conversion to
MFBs, ECM synthesis and cell contraction.
Results
Scleraxis is sufficient and necessary for induction of
cardiac ECM gene expression
We previously demonstrated that Scx directly regu-
lates the expression of Col1a2, one of two component
chains of type I collagen, in cardiac MFBs in vitro via
conserved promoter E-boxes, and others have shown
that Scx up-regulates the Col1a1 chain in tenocytes
[19]. However, while type I collagen is the primary
component of the cardiac ECM, it is unclear whether
Scx plays a broader regulatory role in ECM gene ex-
pression, thus we examined this possibility using gain-
and loss-of-function approaches. In isolated primary
rat pMFBs, an intermediate phenotype between FBs
and MFBs [3, 12, 16], Scx induced expression of the
major cardiac fibrillar collagens (Col1a1, Col1a2,
Col3a1, Col5a1), but not non-fibrillar Col4a1 (Fig. 1a),
suggesting that fibrillar collagens were specifically im-
pacted, and that our results do not represent a gen-
eral effect on collagen expression. Several
proteoglycans were up-regulated by Scx, including
Fmod, Lum and Dcn (Fig. 1b), similar to results re-
ported for proteoglycan regulation by Scx in cardiac
valves [20].
Scx over-expression significantly increased Mmp2 and
Mmp3 expression, but decreased Mmp9 and Mmp11
(Fig. 1c). In agreement with these results, Scx transiently
increased proMMP2 activity by over fivefold (concomi-
tant with a loss of mature MMP2 activity), but decreased
combined MMP9/proMMP9 activity within 24 h
(Fig. 1d). By 48 h, proMMP2 and combined MMP9 ac-
tivity returned to control levels. Some MMPs (e.g.
Mmp2, Mmp3) may thus be under direct transcriptional
control by Scx.
We confirmed that Scx is required for ECM gene ex-
pression via shRNA-mediated loss-of-function in pri-
mary rat cardiac pMFBs. We generated a novel
adenovirus encoding a Scx shRNA (AdshScx), which
rapidly and potently attenuated Scx expression but had
no effect on paraxis, a transcription factor with the
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highest homology to Scx (Fig. 2a) [21]. Scx expression
was lost even after treatment with TGFβ, which we have
shown potently induces Scx expression (Fig. 2b) [6, 18].
Scx knockdown attenuated expression of the same fibril-
lar collagens induced by Scx over-expression, and did
not affect Col4a1 expression (Fig. 2c, d). Scx knockdown
similarly reduced expression of several proteoglycans, in-
cluding Fmod, Lum and Dcn, complementing the over-
expression results (Fig. 2e). Scx loss reduced Mmp2 and
Mmp3 expression, while inducing Mmp9 and Mmp11
(Fig. 2f ). Together, these results indicate that Scx exerts
broad control of genes regulating ECM synthesis and
turn-over.
Cardiac fibroblast phenotype regulation by scleraxis
Increased ECM expression is a hallmark of FB to MFB
phenotype conversion. Given Scx’s regulation of a broad
variety of ECM genes, we hypothesized that Scx governs
cardiac FB phenotype, thus we assayed a broad panel of
FB and MFB markers following Scx gain- or loss-of-
function. Scx over-expression in cardiac pMFBs in-
creased synthesis of nearly all markers tested (Fig. 3a, b),
including the collagen receptor DDR2, EDA-Fn/Fn1,
vimentin/Vim and periostin/Postn, an integrin ligand im-
plicated in fibrosis of various tissues and cardiac FB spe-
cification [22, 23]. Scx knockdown conversely decreased
all markers (Fig. 3c), suggesting reversion away from the
MFB phenotype. Luciferase assay demonstrated that Scx
significantly transactivated the Vim, Mmp2 and Fn1
gene promoters (Fig. 3d), supporting that Scx’s effects
are primarily due to direct target gene transactivation ra-
ther than by a secondary mediator.
Scx regulates target gene expression via interaction
with DNA promoter cis E-box elements [6, 18]. We pre-
viously showed that Scx’s basic DNA-binding and helix-
loop-helix protein-binding domains are functionally crit-
ical, with deletion of the basic domain resulting in a
dominant negative mutant [6, 18]. A Scx mutant lacking
both domains (ScxΔΔ) had no effect on transactivation
of the human COL1A2 promoter, failed to attenuate
Scx-mediated transactivation and did not alter the ex-
pression of fibrillar collagens or FB/MFB markers in
pMFBs, suggesting that this double mutant is inactive,
Fig. 1 Scleraxis up-regulates matrix target genes. a–c Assay of
collagen (a), proteoglycan (b) and matrix metalloproteinase (c) mRNA
expression by qPCR following over-expression of Scx (AdScx) in primary
rat cardiac proto-myofibroblasts compared to controls (AdGFP) reveals
numerous matrix genes are induced; n = 3. d Protein lysates from
AdGFP- or AdScx-infected primary rat cardiac proto-myofibroblasts
were assayed for MMP activity by gel zymography. Zymograms were
obtained 24 or 48 h following infection and revealed transient
induction of proMMP2 and loss of MMP9 following Scx over-
expression; C, control recombinant human MMP2 protein; n = 3.
*P < 0.05 vs AdGFP, #P < 0.05 vs corresponding 24 h time point
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and indicating that the transcriptional activity of Scx is
required for regulating target gene expression
(Additional file 1: Figure S1).
Scleraxis directly regulates αSMA gene expression
Since Scx induced the MFB phenotype, we examined the
effect of Scx on expression of αSMA/Acta2, a contractile
protein not typically expressed in cardiac FBs, but which
is sharply up-regulated during conversion to MFBs [3,
6]. Scx knockdown reduced (Fig. 4a, b) while over-
expression induced αSMA expression (Fig. 4c) and in-
corporation into stress fibers (Fig. 4d), a characteristic of
MFBs [12]. In agreement with this finding, Scx induced
cell contraction of cardiac pMFBs (Fig. 4e, f ). Intri-
guingly, knockdown of Scx completely attenuated cell
contraction induced by TGFβ (Fig. 4e, g), demonstrating
a requirement for Scx in this process.
We tested whether αSMA is a direct Scx gene target.
The rat αSMA proximal promoter contains two well-
characterized E-boxes critical for cis regulation (Fig. 4h)
[24, 25]. Scx transactivated the αSMA promoter nearly
tenfold, and mutating these E-boxes attenuated pro-
moter transactivation by Scx (Fig. 4i). Electrophoretic
mobility shift assay demonstrated that Scx forms com-
plexes with the intact but not mutated E-boxes (Fig. 4j).
Chromatin immunoprecipitation confirmed this inter-
action; however, due to their close proximity (32 nucleo-
tide separation) we could not resolve whether Scx
bound to one or both E-boxes. The amount of DNA-
bound Scx increased by over threefold in cardiac MFBs
Fig. 2 Cardiac matrix gene expression is attenuated by scleraxis knockdown. a Primary cardiac proto-myofibroblasts exhibited loss of Scx but not
paraxis mRNA following infection with adenovirus encoding an shRNA targeting Scx (AdshScx) but not control shRNA (AdshLacZ) for 72 h (assayed
by qPCR). Results were normalized to the respective AdshLacZ sample; n = 3. b Cells treated as in (a), with or without 10 ng/mL TGFβ or vehicle,
were assayed for Scx protein expression 72 h after infection and results normalized to α-tubulin; n = 4. AdshScx attenuated Scx protein expression
even in the presence of TGFβ. c–d Fibrillar collagen mRNA (c) and nascent soluble 150 kDa collagen I protein (d) expression was down-regulated
following Scx knockdown (assayed by qPCR or western blotting, respectively), with cell treatment and normalization as in (a); n = 3. e–f The
expression of mRNAs encoding several proteoglycans (e) and matrix metalloproteinases (f) (assessed by qPCR) was reduced following Scx
knockdown; n = 3. *P < 0.05 vs corresponding AdshLacZ control
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compared to FBs (Fig. 4k), congruent with increased
Scx-mediated αSMA expression during phenotype con-
version (Fig. 4c, d). This data contrasts with a previous
report in mesangial cells reporting that Scx was capable
of binding only to the second E-box, resulting in an in-
hibitory effect on αSMA expression [26]. Our results
demonstrate that Scx activity across cell types is highly
variable and requires empirical testing, and suggests
unique roles for Scx in specific tissues.
Scleraxis is required for cardiac fibroblast gene
expression in vivo
Our ex vivo data revealed that Scx regulates FB pheno-
type and ECM synthesis, thus we assessed its in vivo role
using knockout mice. Scx loss induces cardiac morpho-
logical anomalies, including altered valve structure,
rounding of the ventricles and involution of the apex,
but the effect on myocardial structure and composition
has not been reported. It is unclear whether such alter-
ations are pathological; however, as noted previously
[15], homozygous null pups were under-represented at
birth. Of 438 pups born, we identified 42 (9.5 %) nulls
(KO), 261 (59.0 %) heterozygotes and 139 (31.4 %) wild
type (WT); furthermore, 10 KO (23.8 % of KO neonates)
died prior to 6 weeks of age. KO pups were runted (body
weight WT 20.2 ± 0.8 g, KO 12.2 ± 0.6; n = 9–12; P <
0.0001). We noted a significant ~30 % hypotrophy of the
heart (heart weight:tibia length WT 5.68 ± 0.15 mg/mm,
KO 4.16 ± 0.11; n = 17–20; P <0.0001). Despite this de-
creased relative size, echocardiography revealed largely
normal function (Additional file 2: Table S1), in agree-
ment with earlier data [15]. Left ventricular end diastolic
diameter, normalized to tibia length, was modestly
(~10 %) but significantly elevated in KO mice and endo-
cardial velocity trended lower, suggesting the existence
of early systolic dysfunction. Such modest changes seem
unlikely to contribute to the elevated mortality in KO
mice, thus the causes of pre- and post-natal mortality re-
main unclear.
We examined net fibrillar collagen expression in car-
diac sections from WT or Scx KO mice histologically
and by immunolabeling, and noted a clear reduction in
collagen staining (Fig. 5a). Notably, collagen fibrils ap-
peared diminished in number and size, and there was
Fig. 3 Scleraxis regulates cardiac fibroblast phenotype. a–c Fibroblast/myofibroblast marker gene mRNA (a, c) and protein (b) expression was
assayed in primary cardiac proto-myofibroblasts following Scx over-expression (AdScx) vs controls (AdGFP) (a, b), or following Scx knockdown
(AdshScx) compared to controls (AdshLacZ) (c), assayed by qPCR or western blot; n = 3. Scx loss induced similar down-regulation of fibroblast and
myofibroblast markers, while Scx over-expression induced marker expression. d Scx transactived the vimentin, MMP2 and fibronectin gene
promoters compared to empty vector control (C) as determined by luciferase reporter assays in NIH-3T3 fibroblasts; n = 3 (vimentin, fibronectin)
or n = 4 (MMP2). *P < 0.05 vs AdGFP (a, b), vs AdshLacZ (c) or vs control empty vector (d)
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considerable reduction of perivascular collagen staining.
The reduction in red/yellow fibers visible with picrosirius
red staining under circularly polarized light is indicative of
a net loss of organized collagen bundles (Fig. 5a). Cardiac
ECM dry weight was reduced up to 49 % (Fig. 5b). Con-
gruent with these data, mRNA and protein (Fig. 5c–d)
levels of the major cardiac fibrillar collagens were dramat-
ically decreased by 30–45 %. As in our ex vivo data, non-
fibrillar Col4a1 expression was unaltered.
Also in agreement with our ex vivo data, ECM alterations
were not limited to collagens: we observed a general de-
crease in proteoglycan expression in the hearts of Scx KO
mice compared to WT, with significant loss of Fmod,Vcan
and Bgn (Fig. 5e). Conversely, decorin expression was un-
disturbed, thus proteoglycan loss was also not universal.
Similar to our ex vivo data, KO hearts exhibited sig-
nificantly reduced mRNA expression of Mmp2, Mmp3
and Mmp9 (Fig. 5f ). This down-regulation correlated
with a generalized loss of activity of both the mature
and latent (pro) forms of MMP2 and MMP9 (Fig. 5g).
Scx gene deletion in vivo thus resulted in altered expres-
sion of collagen, proteoglycans and MMPs, which closely
recapitulated our knockdown data.
Scx regulated cardiac FB phenotype ex vivo (Figs. 3, 4),
thus we assayed relevant marker expression in WT and
KO hearts. All markers tested were significantly down-
regulated by over 50 % in Scx KO mice (Fig. 5h, i). In
agreement with our data demonstrating direct regulation
of αSMA expression by Scx (Fig. 4), we also observed a
significant loss of αSMA protein in Scx KO hearts
(Fig. 5i). Since αSMA is not expressed in cardiac FBs in
the healthy heart, this loss likely reflects changes in vas-
cular smooth muscle cells.
Scleraxis is required for Smad3-mediated gene expression
It is unclear whether the in vivo alterations in cardiac FB
gene expression reflect an inherent transcription defect
in these cells, thus we tested whether Scx could rescue
gene expression in cardiac pMFBs from WT and KO
mice via adenoviral transgene delivery. KO cells exhib-
ited virtually no Scx expression, but AdScx drove Scx to
approximately sixfold of WT expression (Fig. 6a). The
significant loss of Vim, Acta2, Fn1, Col1a1, Col1a2 and
Col3a1 observed in these cells was similarly rescued
(Fig. 6a). Loss of expression of these genes in Scx null
cells is thus not due to a generalized defect in the tran-
scription mechanism, but rather is specific to loss of Scx
transcriptional activity. In accordance with our earlier
data, neither loss nor rescue of Scx altered Col4a1
expression.
We previously demonstrated strong synergy between
Scx and Smad3 in regulating Col1a2 expression, and
that deletion of Scx-binding sites in the Col1a2 pro-
moter attenuated Smad3 transactivation of this promoter
[18]. We therefore examined the impact of Scx knock-
down on Smad3-mediated collagen gene expression in
primary pMFBs. Smad3 induced expression of the fibril-
lar collagens Col1a1, Col1a2 and Col3a1, but this was
significantly attenuated by Scx knockdown (Fig. 6b).
Given this dependence of Smad3 activity on Scx, we
tested whether Smad3 and Scx physically interact using
co-immunoprecipitation of Scx and Smad3. We ob-
served a clear interaction between the two proteins
(Fig. 6c), in agreement with a recent report that Smad3
binds Scx in tendons [27]. Deletion of the helix-loop-
helix protein interaction domain of Scx attenuated bind-
ing to Smad3.
Given the close physical and functional relationship
between Scx and Smad3, we examined the effect of Scx
loss on Smad3 recruitment to the Col1a2 gene promoter
by chromatin immunoprecipitation. Smad3 binding to
the Col1a2 gene promoter Smad binding element was
significantly reduced in Scx KO hearts compared to WT
(Fig. 6d), and re-ChIP demonstrated a similar loss of
(See figure on previous page.)
Fig. 4 Scleraxis regulates cardiac myofibroblast α-smooth muscle actin expression and cell contraction. a–b αSMA mRNA (a) and protein (b) expres-
sion were assayed by qPCR or western blot, respectively, following knockdown of Scx (AdshScx) in primary cardiac proto-myofibroblasts, showing
attenuated αSMA expression compared to control (AdshLacZ); n = 3. c Scx over-expression (AdScx) up-regulated αSMA expression in primary rat
cardiac proto-myofibroblasts as determined by mRNA or protein expression (qPCR or western blot, respectively); n = 3. d Induced αSMA was
incorporated into stress fibers, as demonstrated by immunocytochemistry, indicating promotion of the myofibroblast phenotype by Scx; 20× objective,
scale bar = 65 μm. e Primary cardiac proto-myofibroblasts seeded onto compressible collagen gel matrices were assayed for gel contraction following
Scx over-expression or knockdown, with or without concomitant 10 ng/mL TGFβ1 to induce contraction. Crosses denote the detected margin of the
collagen gel. f–g Quantification of gel contraction images, reported as the percentage of the maximum contraction induced by 10 % FBS,
demonstrates that Scx over-expression induces cell contraction (f), while Scx knockdown attenuates TGFβ1-induced contraction (g); n = 6 ((f) except
AdGFP + TGFβ and AdScx + TGFβ; n = 3 each) or n = 3 (g). *P < 0.05 vs AdshLacZ (a–b), vs AdGFP (c, f) or vs AdshLacZ + vehicle (g), #P <0.05 vs vehicle
controls (f) or vs AdshLacZ + TGFβ (g). h Alignment of putative Scx-binding E-boxes (E1 and E2; dashed lines) in the proximal rat, mouse and human
αSMA promoters. Asterisks and periods denote nucleotides conserved across three or two species, respectively. i Mutation of one or both E-boxes
(mE1, mE2) attenuates transactivation of the rat αSMA proximal promoter by Scx as determined by luciferase reporter assay; n = 3. j Electrophoretic
mobility shift assays demonstrate Scx-binding to E-boxes E1 and E2; this binding is abolished when the E-boxes are mutated (mE1 and mE2). NS,
non-shifted lane; S, shifted lane; CC, 500× cold competition. The arrow denotes the shifted complex. k Scx-binding to the αSMA gene promoter is
significantly enriched in cardiac myofibroblasts (MyoFb) compared to fibroblasts (Fb) as determined by chromatin immunoprecipitation assay with
qPCR quantification of Scx-bound DNA; n = 3. *P < 0.05 vs control empty vector (i) or vs Fb (k), #P < 0.05 vs scleraxis + non-mutated promoter (i)
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Smad3-bound RNA polymerase II. This effect was reca-
pitulated in a dose-dependent manner by delivering a
Scx dominant-negative mutant ScxΔBD [18] to human
adult ventricular MFBs (Fig. 6e), suggesting that the mu-
tant exerts its effect by sequestering Smad3 away from
the promoter. Together, these results demonstrate that
Smad3 signaling is attenuated in the absence of Scx due
to impaired transcriptional complex formation.
Loss of cardiac fibroblasts in scleraxis null mice
Scx loss clearly impairs cardiac FB function, but it is also
possible that cardiac FB number may be negatively im-
pacted. We analyzed cardiac cell identity by flow cytom-
etry using markers for cardiomyocytes (α-myosin heavy
chain, αMHC), FBs (DDR2), vascular smooth muscle
(αSMA) and endothelial cells (CD31) (Additional file 3:
Figure S2). The number of αSMA+ and DDR2+ cells was
significantly reduced with a similar trend in CD31+ cells
(Fig. 7a–c). Since αSMA is primarily expressed by vascu-
lar smooth muscle cells in the healthy heart, the cardiac
vasculature may be negatively impacted in these animals.
A significant ~25 % decrease in capillary density in KO
hearts further indicates reduced vascularity (Additional
file 4: Figure S3A–B). Although αMHC+ cardiomyocyte
number was not affected by Scx knockout, we found
that cardiomyocyte cross-sectional area significantly de-
creased by 29 % in KO mice (Additional file 4: Figure
S3C–D). The net hypotrophy noted in KO hearts thus
appears to be due to reduced myocyte volume.
DDR2 is enriched in cardiac FBs and not expressed in
cardiomyocytes [28, 29]. Nearly half of all DDR2+ cells
were lost in Scx KO hearts (Fig. 7b–c), and cardiac tis-
sue sections exhibited greatly reduced numbers of
DDR2-expressing FBs (Fig. 7d). It is unlikely that cell
loss is due to increased cell death, as shRNA-mediated
knockdown of Scx had no such effect (Additional file 5:
Figure S4). The loss of cardiac fibroblasts may be re-
sponsible for the decrease in cardiomyocyte size, since
co-culture of fibroblasts with adult cardiomyocytes pro-
motes hypertrophy [30].
We hypothesized that missing DDR2+ cells in KO
hearts may reflect an altered cell fate of FB precursors,
rather than actual cell loss. Differentiation of cardiac FBs
during development, with further phenotype refinement
to MFBs, has been ascribed to epithelial-to-
mesenchymal transition (EMT) [31, 32]. In KO hearts,
we observed a ~30 % loss of mRNA expression of Tcf21
(Fig. 7e), a transcription factor required for EMT of car-
diac FBs from proepicardial organ precursors [31], thus
we assayed EMT marker expression using a selection of
epithelial and mesenchymal marker genes that, while not
individually definitive for EMT, have collectively been
widely used in the literature to assess EMT progression.
Immunofluorescence revealed a notable loss of labeling
for the mesenchymal marker Twist1 in KO hearts, with
fewer Twist1-positive nuclei consistent with a loss of fi-
broblasts (Fig. 7f ). mRNA of all mesenchymal markers
tested (Snai1, Twist1, Zeb1) was significantly down-
regulated by 25–40 % in KO hearts, while epithelial
markers (Dsp, Par3, Cldn1) increased (Fig. 7g). While a
definitive assessment of embryonic EMT is beyond the
scope of the present study, this result is consistent with
an attenuation of EMT during the developmental
process. Knockdown of Scx in pMFBs significantly re-
duced mesenchymal marker expression, while Scx over-
expression had the opposite effect (Fig. 7h, i). Scx dose-
dependently transactivated the Snai1 and Twist1 gene
promoters (Fig. 7j).
Strikingly, over-expression of Scx in the A549 human
lung epithelial cell line caused a potent up-regulation of
a variety of FB and mesenchymal markers while redu-
cing epithelial marker expression (Fig. 7k), demonstrat-
ing that Scx was sufficient to induce EMT in these cells.
Furthermore, Scx did not alter expression of the tendon
marker Tnmd in A549 cells, indicating that Scx induced
a FB rather than a tenocyte phenotype. This result is in
contrast to C3H10T1/2 mouse embryonic FBs, in which
(See figure on previous page.)
Fig. 5 Scleraxis null mice exhibit reduced cardiac extracellular matrix and fibroblast marker gene expression. a Cross sections of hearts from wild
type (WT) or Scx null (KO) hearts stained for fibrillar collagen using picrosirius red (BF, bright-field; POL, polarized light), Masson’s trichrome or via
immunolabeling for total collagen I (red; plus DAPI nuclear staining in blue) revealed matrix loss in KO hearts; collagen I: 20× objective, scale bar
= 35 μm; picrosirius/trichrome: 40× objective, scale bar = 66 μm. The blue color channel was extracted from the Masson’s trichrome sections for
improved visualization. Samples are representative of at least three individual animals of each genotype. b Decellularized and dehydrated cardiac
ventricular ECM from WT or KO mice was normalized to cardiac ventricular wet mass or tibia length and revealed ECM loss in KO hearts; n = 7
animals of each genotype. c–d Fibrillar collagen gene expression by qPCR (c) or western blotting normalized to Gapdh or β-actin (d) was
decreased in Scx KO hearts compared to WT; n = 3 ((c) or collagen I blot in (d)) or n = 4 (collagen III and IV blots in (d)). Collagen I protein
expression was the sum of the α1 and α2 isoforms. e–f The expression of mRNAs encoding several proteoglycans (e) and matrix metalloproteinases (f)
(assessed by qPCR) was lost in Scx KO hearts; n = 3 animals of each genotype. g MMP2 and MMP9 activity (latent pro-form and mature, assayed by gel
zymography) of protein lysates from WT or KO hearts was reduced in null animal hearts; n = 3 animals of each genotype. *P < 0.05 vs WT. h–i
Fibroblast/myofibroblast marker gene mRNA (h) and protein (i) expression was assayed in WT and Scx KO mice, assayed by qPCR or western blot;
n = 3 ((h) and vimentin in (i)) or n = 4 (DDR2 and αSMA in (i)). Scx loss induced similar down-regulation of fibroblast and myofibroblast markers.
*P < 0.05 vs WT
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Scx induced FB and mesenchymal markers as well as
Tnmd (Additional file 6: Figure S5), in agreement with a
recent report that Scx induces a tenocyte fate in these
cells [33]. We note that induction of FB and mesenchy-
mal markers in either cardiac pMFBs or C3H10T1/2
cells required adenoviral gene delivery of Scx at only 10
MOI—an order of magnitude less than the amount re-
quired to induce EMT in A549 cells (100 MOI). The
ability of Scx to regulate a mesenchymal FB phenotype
thus appears to be cell type-specific and dose-
dependent. TGFβ induces EMT in A549 cells [34], and
we observed potent up-regulation of Scx by TGFβ simi-
lar to our findings in cardiac FB (Fig. 7l) [18]. The in-
duction of mesenchymal marker expression by TGFβ
was significantly attenuated by our Scx dominant-
negative mutant ScxΔBD, demonstrating a requirement
for Scx in this process (Fig. 7m).
Discussion
The transcriptional regulators that govern FB phenotype
and function are poorly defined. Our study demonstrates
for the first time that Scx is a critical regulator of virtu-
ally all hallmarks of the mesenchymal phenotype of FBs
and MFBs. This includes both sufficiency and necessity
for the ex vivo and in vivo expression of numerous ECM
genes, FB/MFB markers, αSMA and cell contraction,
and mesenchymal markers—expression patterns that vir-
tually define the FB and MFB phenotypes. We also pro-
vide the first evidence that Scx could potentially be
important for EMT programming of FBs in the
myocardium.
Tendons and cardiac valves possess a collagen-rich
ECM, and Scx KO profoundly affects both tissues. Scx
deletion results in the loss of force-transmitting tendons
due to a failure of tendon progenitor differentiation,
disorganization of the tendon matrix and loss of type I
collagen production via an undefined mechanism [17].
Conversely, Scx commits embryonic stem cells to a
tenocyte fate and induces expression of Tnmd, a direct
Scx target gene in C3H10T1/2 cells [33, 35, 36]. Scx KO
mice exhibit thickened cardiac valves with altered colla-
gen expression and fiber organization due to reduced
valve precursor cell differentiation, although Scx target
gene identity was unclear [15]. Scx thus appears to regu-
late progenitor cell behavior and tissue structure in
ECM-rich environments through undefined mecha-
nisms, resulting in significant cell fate and ECM alter-
ations when this function is disturbed.
Our results indicate that Scx performs a fundamental
role in FB cell fate/phenotype in the collagen-rich myo-
cardium, and for the first time reveal the underlying
mechanisms. Our identification of Vim, MMP2, Fn1,
Acta2, Snai1 and Twist1 as novel transcriptional targets
of Scx (Figs. 3d, 4h–k, 7j) explains the loss of expression
of these genes following Scx loss, and complements
previous work by our laboratory and others identifying
the Col1a1 and Col1a2 genes as additional direct targets
[6, 18, 19]. We anticipate that other genes assayed here,
including Col3a1, Col5a1, Fmod, Lum, DDR2, Myh10
and Postn, are likely to also be direct transcriptional tar-
gets given the close agreement between their expression
and Scx. However, our work also reveals the critical
interplay between Scx and Smad3, including physical
interaction (Fig. 6b–c), resulting in impaired assembly of
a transcriptional complex at the Col1a2 promoter in Scx
null mice or at the COL1A2 promoter following treat-
ment of human adult ventricular FBs with our
dominant-negative Scx mutant (Fig. 6d–e), as well as
complete attenuation of TGFβ-mediated pMFB contrac-
tion (Fig. 4g). The dominant-negative mutant lacks a
DNA-binding domain, and we had hypothesized that
this mutant acted by sequestering key binding partners
away from target genes [18]. Here we demonstrate that
this mutant dose-dependently reduced Smad3-binding
(See figure on previous page.)
Fig. 6 Requirement of scleraxis for Smad3-mediated gene expression. a Over-expression of Scx (AdScx) for 24 h rescues expression of vimentin, αSMA,
ED-A fibronectin and fibrillar collagen mRNA (by qPCR) in primary cardiac proto-myofibroblasts obtained from Scx null mice compared to controls
(AdGFP); n = 3 independent samples per genotype. Impaired collagen expression in Scx null cells is thus due to Scx loss and not a defect in the basal
transcriptional machinery. b Up-regulation of fibrillar collagen mRNA expression by Smad3 (assessed by qPCR) is attenuated following Scx knockdown
(AdshScx) compared to shRNA control in cardiac proto-myofibroblasts (AdshLacZ); n = 3. c Scx and Smad3 physically interact. Expression vectors for
HA-tagged Scx and myc-tagged Smad3 were individually or jointly transfected into NIH-3T3 fibroblasts, then immunoprecipitated (IP) by anti-HA
antibodies and subjected to western blotting with anti-myc antibodies (upper panels). Non-immunoprecipitated input and non-specific IgG antibodies
were employed as positive and negative controls, respectively. Equal loading of transfected whole-cell lysates is shown by anti-HA and anti-myc
western blots. Conversely, co-immunoprecipitation with Smad3 was not observed when a Scx mutant lacking its protein-interaction domain (HA-Scler-
axisΔHLH) was employed (lower panels). d Smad3 and RNA polymerase II interaction with the Col1α2 gene promoter is significantly impaired in cardiac
fibroblasts derived from Scx KO mouse hearts compared to WT, as assessed by chromatin immunoprecipitation (anti-Smad3 antibody vs
non-specific IgG antibody) and re-ChIP (anti-RNA Pol II antibody vs non-specific IgG antibody) followed by qPCR, indicating that Scx loss
impairs Smad3 signaling and Smad3-mediated recruitment of the transcription complex to the Col1α2 gene promoter; n = 3 independent
samples per genotype. e Adenovirus-mediated over-expression of a DNA-binding Scx mutant (AdScxΔBD; 10, 50 or 100 MOI) in human
ventricular myofibroblasts attenuates Smad3 and RNA polymerase II recruitment to the Smad-binding element of the Col1α2 gene
promoter compared to control (AdGFP) performed as in (d); n = 3. *P < 0.05 vs WT (a) or vs AdGFP + AdshLacZ (b) or vs IgG (d–e),
#P < 0.05 vs KO + AdGFP (a) or vs AdSmad3 + AdshLacZ (b) or vs WT (d) or as indicated (e)
Bagchi et al. BMC Biology  (2016) 14:21 Page 11 of 21
Fig. 7 (See legend on next page.)
Bagchi et al. BMC Biology  (2016) 14:21 Page 12 of 21
to the COL1A2 promoter, in turn reducing recruitment
of RNA polymerase II (Fig. 6e), in support of this model.
Together, these results provide the mechanism for our
previous observation of both the synergy between
Smad3 and Scx, as well as their mutual requirement for
full transcriptional activity on the COL1A2 promoter
[18], and suggests a model for how Scx may interact
with Smad3 or other binding partners to modulate add-
itional downstream genes.
In both tendons and cardiac valves, Scx gene deletion
resulted in a failure of progenitor cells to specify, differ-
entiate and/or proliferate, but without apoptosis [15, 17].
It was also recently shown that Scx is required for ten-
don stem cell differentiation to tenocytes [37]. Our data
fits with the theme of Scx behaving as a cell fate medi-
ator. EMT plays an important role in the generation of
FBs in the adult myocardium [31, 32], and we show that
Scx directly transactivates the gene promoters of the
mesenchymal markers Vim, Snai1 and Twist1 (Figs. 3d,
7j). The loss of mesenchymal marker expression in Scx
KO hearts, with increased epithelial marker expression,
supports the possibility that Scx may be important in
the developmental EMT programming of FBs from epi-
thelial precursors (Fig. 7n), and we show for the first
time that Scx is sufficient to reprogram A549 epithelial
cells to a mesenchymal, FB-like phenotype (Fig. 7k).
TGFβ/Smad3 signaling is a potent driver of EMT [38].
We found that TGFβ up-regulated Scx expression in
A549 cells, and ScxΔBD significantly attenuated TGFβ-
mediated mesenchymal marker induction (Fig. 7k, m),
demonstrating a requirement for Scx in this process and
consistent with a central role for scleraxis in mediating
TGFβ/Smad3 downstream events. The loss of FBs in Scx
KO hearts may thus reflect a failure of EMT. The
regulation of EMT in the embryonic myocardium by Scx
is an intriguing focus for future study, requiring direct
assessment of EMT and nascent FB numbers during de-
velopment. FB to MFB conversion is an extension of this
EMT, with further refinement of the cell phenotype to
increase ECM synthesis, induce expression of αSMA
and other MFB genes, and initiate cell contraction. Here,
too, Scx was both necessary and sufficient to govern
broad ECM gene expression (Figs. 1, 2, 5), to directly
transactivate the αSMA promoter (Fig. 4i–k), to facilitate
cell contraction (Fig. 4e–g) and to regulate FB/MFB
marker gene expression (Figs. 3, 5h–i). Scx thus governs
the main features of fibroblastic cells in the heart along
the full phenotype continuum.
In the developing mouse heart, high pericardial ex-
pression of scleraxis was observed at embryonic day 11
[39]. This is consistent with the localization of proepi-
cardial organ-derived Scx+ cells at the epicardial surface
at the same time point reported by Katz et al. [40]. How-
ever, Katz also noted that Scx+ cells had already mi-
grated into the right ventricle by E10.5, suggesting they
had undergone a prior EMT event, and migration con-
tinued to at least E13.5. Approximately two thirds of
WT1+ cells in the Katz study did not express Scx, and of
the Scx+ cells, 60 % gave rise to fibroblasts, epicardium
and other derivatives, 24 % gave rise to endothelial cells,
7.8 % gave rise to smooth muscle cells, and 6.6 % gave
rise to cardiomyocytes. Thus it appears that a sub-
population of cells expressing Scx gives rise to FBs, al-
though the exact size of this cell population remains un-
clear. However, the existence of such a sub-population
could explain why Scx KO hearts lacked only ~50 % of
FBs, rather than exhibiting the nearly complete loss that
was observed in Tcf21 null hearts [31]. Tcf21 KO and
(See figure on previous page.)
Fig. 7 Loss of cardiac fibroblasts following scleraxis deletion in vivo. a–b Representative flow cytometry histograms of WT and Scx KO heart single-cell
suspensions show cardiac cells stained for αSMA (a) or DDR2 (b) in WT (dotted line) and KO (solid line) mice. Unstained cell sample was used as control
(shaded histogram). c Total αMHC+, αSMA+, CD31+ or DDR2+ stained events per 5 × 104 events in WT or KO mice normalized to WT
counts demonstrating normal cardiomyocyte counts but reduced numbers of fibroblasts; n = 3 independent samples per genotype. d
Representative cardiac sections from WT and KO mice immunolabeled for DDR2 confirm the loss of DDR2+ cells; 63× objective, scale bar
= 20 μm. e qPCR assay of Tcf21 mRNA expression in WT and Scx KO mice; n = 3 independent samples per genotype. f Cardiac sections
as in (d) were immunolabeled for Twist1 expression (red; DAPI nuclear staining in blue); 20× objective, scale bar = 64 μm. g Cardiac mRNA
from WT and Scx KO mice was assayed for expression of mesenchymal and epithelial marker genes by qPCR, indicating reduced
epithelial-to-mesenchymal transition in KO hearts; n = 5 independent samples per genotype. h–i Cardiac proto-myofibroblasts were
subjected to Scx knockdown (h) or over-expression (i) and EMT markers assessed by qPCR, indicating that Scx regulates mesenchymal
marker gene expression; n = 3. j Scx dose-dependently transactivates the Snai1 and Twist1 proximal gene promoters as determined by
luciferase assay or GFP western blot, respectively; n = 3. k Representative fibroblast/myofibroblast, mesenchymal, epithelial and tendon
marker gene mRNA expression was assayed in A549 epithelial cells following Scx over-expression (AdScx) vs controls (AdGFP), assayed by
qPCR; n = 3. l Scx mRNA expression was assayed by qPCR in A549 cells following treatment with 2.5 ng/mL TGFβ or vehicle; n = 4. m
Mesenchymal marker gene mRNA expression was assayed in A549 cells following Scx dominant negative mutant over-expression
(AdScxΔBD) vs controls (AdGFP), with or without treatment with 2.5 ng/mL TGFβ or vehicle; n = 3. *P < 0.05 vs WT (c, e, g), vs AdshLacZ
(h), vs AdGFP (i, k, m), vs control transfected vector (j) or vs vehicle (l); #P <0.05 vs AdGFP + TGFβ (m). n Putative model of action of Scx.
Top panel, Scx is required for cardiac fibroblast to myofibroblast phenotype conversion (solid arrow), and possibly for transition of
epithelial precursors to the mesenchymal/fibroblast phenotype (dashed arrow). Bottom panel, Scx is sufficient to directly transactivate
numerous genes that characterize the myofibroblast phenotype, and is required for TGFβ/Smad3-mediated gene expression by facilitating
Smad3 and RNA polymerase II interaction at target gene promoters such as Col1α2
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Scx KO hearts bear a striking physical resemblance to
one another, including right-side enlargement, and
rounding and involution of the apex, and Tcf21 has been
shown to regulate Scx expression in Sertoli cells [15,
31, 41]. Scx KO may thus partially phenocopy Tcf21
loss, and investigation of a similar regulatory regime
in the myocardium is warranted. In this regard, it is
noteworthy that Tcf21 was down-regulated in Scx KO
hearts (Fig. 7e). An intriguing possibility is that a net
loss of fibrillar collagen and extracellular matrix, and
thus structural support, in the thinner and physically
weaker right ventricular wall may lead to specific re-
modeling of this chamber, consistent with the right
ventricular enlargement observed in both Scx KO and
Tcf21 KO hearts. It is also notable that, unlike Tcf21
KO hearts, we observed evidence of reduced smooth
muscle and endothelial cell numbers. This is consist-
ent with Katz’ report of Scx+ cells contributing to
these cell populations, and may reflect an impairment
in the development of these populations. Katz also
noted that Scx+ cells contributed in a minor fashion
to the cardiomyocyte population. While we saw no
evidence of a decline in cardiomyocyte number, we
did note a reduction in cardiomyocyte size
(Additional file 4: Figure S3C–D), suggesting that Scx
may play a role in the growth of these cells. However,
we cannot rule out the possibility that this alteration
may instead reflect a response of cardiomyocytes to
the altered extracellular matrix environment present
in Scx KO hearts.
The FBs that do arise in the Scx KO heart appear to
be functionally impaired: pMFBs isolated from KO
hearts exhibited dramatic loss of Col1a1, Col1a2,
Col3a1,Vim, Fn1 and Acta2, demonstrating a clear func-
tional deficit in these cells (Fig. 6a). However, this deficit
could be corrected simply by restoring Scx expression,
further demonstrating the critical central role of Scx in
fibroblastic gene expression. Furthermore, this effect was
dependent on intact DNA-binding and protein-
interaction moieties within Scx, as a mutant lacking
these sequences failed to impact gene expression
(Additional file 1: Figure S1).
Transition of FBs to MFBs in connective tissues of the
heart, lungs, liver, kidney and dermis is integral to
pathologic ECM remodeling and scar formation [42].
While the identity of definitive FB/MFB markers re-
mains controversial, Scx induced and was required for
the expression of virtually all commonly-employed FB/
MFB markers, including DDR2, Fn1, Myh10, Vim and
Acta2 (Figs. 3, 4 and 5) [3, 12, 28, 29]. Scx also induced
the incorporation of αSMA into stress fibers (Fig. 4d), a
hallmark of full conversion to MFBs [16], and we found
that Scx potently up-regulated Postn (Fig. 3a), which is
implicated in cardiac fibrosis [23, 43, 44]. Promotion of
the MFB cell fate and induction of ECM synthesis by
Scx is clearly congruent with a role in cardiac fibrosis.
Further investigation into the specific role of Scx in
cardiac fibrosis and ECM remodeling is thus an import-
ant next step, particularly given our finding that pro-
fibrotic TGFβ/Smad3 signaling potently up-regulate Scx
expression [18]. Investigation of the impact of Scx loss
on cardiac fibrosis is beyond the scope of the present
inquiry, but the potential for Scx to play a pathogenic
role is clear. The cardiac developmental defects noted in
Scx KO mice, including abnormal valve formation, pre-
vents their use in experimental models of cardiac dys-
function such as pressure overload, infarction or β-
agonist administration, but conditional gene deletion of-
fers an alternative strategy to address this important
question in future studies. The central role of Scx in FB
phenotype and ECM synthesis demonstrated here should
spur investigation into methods of attenuating Scx func-
tion in order to develop novel therapeutic strategies for
fibrosis, which at present are completely lacking [45].
Conclusions
The results presented here identify the transcription fac-
tor scleraxis as not only a potent activator of ECM gene
expression and synthesis in vitro and in vivo, but also
and for the first time as a key regulator of the phenotype
of cardiac fibroblasts. Epithelial cells, mesenchymal fi-
broblasts and myofibroblasts represent a cellular con-
tinuum from development to disease, and our data
demonstrate the central role of scleraxis in the transition
of cells through these phenotypes. Although a definitive
role for scleraxis in EMT during fibroblast formation in
cardiac development remains to be demonstrated, scler-
axis induced and was required for EMT in A549 epithe-
lial cells, and the loss of fibroblasts concomitant with
up-regulation of epithelial markers (and loss of mesen-
chymal markers) in the scleraxis null heart is consistent
with a role in developmental EMT. Fibroblast-to-
myofibroblast transition was attenuated by scleraxis gene
deletion or knockdown, and was induced by scleraxis
over-expression. Given the significant contributory role
of fibroblast activation in fibrotic diseases, and the con-
servation of key signaling pathways, including TGFβ/
Smad in fibrosis across tissue types, scleraxis represents
an attractive new target for the development of therapies
targeting fibrosis in the heart and other tissues.
Methods
Animal studies
The generation of scleraxis null mice (strain Scxtm1.1Stzr;
MGI:3716564) has been described previously [17]. Mice
were on a C57BL/6 background, and wild type litter-
mates were used as controls. Animals were provided
with food and water ad libitum and maintained on a 12/
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12 day/night cycle. All animals were cared for as pre-
scribed by the guidelines of the Canadian Council on
Animal Care (CCAC) and the University of Manitoba
Animal Care Committee. Wild type and knockout animals
were analyzed at 6–10 weeks of age. For analyses of gene
expression in wild type and scleraxis null hearts, ventricu-
lar myocardium was dissected clear of the atria and valves.
Antibodies
Antibodies used throughout the study are listed in
Additional file 2: Table S2.
Echocardiography
Non-invasive murine transthoracic echocardiography
was performed on 6-week-old, non-sedated animals
using a Vivid 7 machine (GE Healthcare), equipped with
a 13 MHz linear probe [46, 47]. Cardiac dimensions and
function were evaluated using 2D and M-mode data col-
lected in long and short parasternal axis views, as well as
tissue Doppler imaging. Data collection and analysis
were performed separately by observers blinded to the
genotype of the animals.
Ventricular ECM mass determination
Cardiac ventricles from WT or scleraxis KO animals
were removed and fragmented. Tissue fragments were
processed for decellularization using a conventional cell
maceration technique with modifications [48, 49].
Briefly, tissues were fixed in 10 % neutral buffered for-
malin. After 4–5 thorough rinses in distilled water, the
tissue fragments were immersed in a 10 % sodium hy-
droxide solution for 4–5 days to remove the cellular ele-
ments. The decellularized tissue was rinsed with water
until it became transparent, then dehydrated in 100 %
methanol followed by freeze-drying to yield dry ECM,
and the dry mass recorded.
Cell culture and treatments
Primary cardiac fibroblasts were isolated from adult
male Sprague Dawley rats via Langendorff perfusion and
enzymatic digestion using 0.1 % collagenase type II
(Worthington Biochemical Corporation) followed by
gentle centrifugation for collection of cells as previously
described [18, 50]. Cells were maintained in DME/F12
media supplemented with 10 % serum, 1 % antibiotics
and 1 mmol/L ascorbic acid. Cells were then passaged
once to P1 (passage 1) proto-myofibroblasts and plated
appropriately for downstream assays [6]. Equilibration of
cells for 24 h in serum-free medium was carried out
prior to all treatments. For over-expression studies, cells
were infected with adenoviruses encoding LacZ
(AdLacZ), GFP (AdGFP) or scleraxis (AdScx) for 24 h;
we have previously shown that AdScx induces physio-
logic levels of scleraxis expression (by approximately
threefold) similar to treatment with TGFβ [6, 18]. For
experiments requiring treatment of cells with TGF-β1,
media was replenished and cells treated for an additional
24 h with recombinant TGF-β1 or vehicle (control). The
ScxΔΔ mutant was generated using nested PCR based
on our previous mutant [6]. Primary rat cardiac proto-
myofibroblasts (5 × 105 cells) were transfected by elec-
troporation (Gene Pulser II, Bio-Rad) at 220 V and
500 μF in 0.5 mL serum-supplemented DME/F12 media
with 2 μg pECE (control) or ScxΔΔ. Total RNA was iso-
lated from these cells 24 h post-transfection and ana-
lyzed for target gene expression. For some studies,
cardiac fibroblasts were isolated from 6-week-old WT
and scleraxis KO mice using Liberase TH Research
Grade (Roche) [51]. Cells from the first passage were
used for adenovirus-mediated gene rescue experiments.
A549 human alveolar epithelial carcinoma cells (ATCC)
were maintained in DMEM high glucose media supple-
mented with 10 % FBS and 1 % antibiotics. Cells were
incubated overnight in 1 % insulin-transferrin-selenium
(ITS; Gibco)-supplemented medium and infected with
adenovirus encoding scleraxis or GFP (control).
C3H10T1/2 mouse embryonic fibroblasts (ATCC) were
cultured and treated similarly as A549 cells. Total RNA
was isolated from these cells and subjected to qPCR
using specific primers.
Generation of shRNA-encoding adenovirus
The BLOCK-iT RNAi Advisor program (Life Technologies)
was used to design shRNA sequences for rat scleraxis gene
knockdown. The two pairs of oligonucleotides were
annealed and cloned into the pENTR/U6 RNAi Entry Vec-
tor following the manufacturer’s instructions (Life Tech-
nologies), then subcloned into pAd/BLOCK-iT-DEST
vector to generate pAd-shScleraxis. The vectors were finally
packaged to produce Ad-shScleraxis adenovirus (AdshScx)
in 293A cells. Viral titer was determined using a commer-
cial kit (Adeno-X Rapid Titer Kit) following manufacturer’s
instructions (Clontech Laboratories, Inc.). P1 rat cardiac
proto-myofibroblasts were infected at various multiplicities
of infection (MOI; 50, 100, 200) for 48 h to determine opti-
mal MOI for further experiments. All experiments were
carried out using MOI 200 for 72 h. Infection control
groups received adenovirus encoding shLacZ (AdshLacZ)






Primary adult rat cardiac fibroblasts were grown in Per-
manox plastic chamber slides (Nunc, Thermo Fisher Sci-
entific) in DME/F12 medium (HyClone, GE Healthcare)
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supplemented with 0.5 % FBS and 500 μmol/L ascorbic
acid. Cells were infected with AdshLacZ (control) or
AdshScx adenovirus at MOI 200 for 48 h. Cell viability
was assayed using the LIVE/DEAD Viability/Cytotoxicity
kit as per manufacturer’s instructions (Life Technolo-
gies). Vital dyes calcein acetoxymethyl ester (calcein
AM) and ethidium homodimer-1 were used to visualize
live (green) and dead (red) cells, respectively, using a
Zeiss Axio Imager M1 epifluorescence microscope with
10× EC Plan-Neofluar objective (NA 0.3). Data was re-
corded as percent cell death compared to control from
three independent experiments (minimum total cell
count of 400); 200 μmol/L H2O2-treated cells were used
as dead cell control.
Quantitative real-time PCR (qPCR)
Total RNA was collected from isolated cells using a kit
as per manufacturer’s directions (Thermo Fisher Scien-
tific). Cardiac tissue RNA was isolated using TRIzol Re-
agent (Ambion, Life Technologies) as per manufacturer’s
instructions. Equal amounts of RNA (25 ng for cells,
50 ng for tissue) were assayed using an iQ5 multicolor
real-time PCR thermocycler (Bio-Rad) using the qScript
One-Step SYBR Green qRT-PCR kit for iQ (Quanta Bio-
sciences). Amplicon abundance was quantified using the
2-ΔΔCT method, and normalized to Gapdh. Primers used
for these reactions are per our previous work or listed in
Additional file 2: Table S3 [6, 18].
Western blotting
Total protein was isolated from cells using radioimmu-
noprecipitation assay buffer (RIPA) comprised of
50 mmol/L Tris pH 7.4, 150 mmol/L NaCl, 1 mmol/L
EDTA, 1 mmol/L EGTA, 0.5 % Na-deoxycholate, 1 %
Triton X-100 and 0.1 % sodium dodecyl sulfate (SDS).
Protease inhibitor cocktail (Thermo Fisher Scientific),
1 mmol/L DTT and 1 mmol/L PMSF were added to the
RIPA buffer prior to use. Mouse tissue lysates were pre-
pared by homogenizing cardiac tissue in protein extrac-
tion reagent type 4 (Sigma-Aldrich). Proteins were
separated under reducing conditions using SDS poly-
acrylamide gel electrophoresis and transferred onto
polyvinylidene difluoride membranes (Pall Corporation).
Blots were probed with specific primary antibodies for
scleraxis [6, 18]: collagen type I (Cedarlane); collagen
type III, type IV or α-tubulin (Developmental Studies
Hybridoma Bank, University of Iowa); Gapdh, DDR2 or
αSMA (Sigma-Aldrich); vimentin or SMemb (Abcam);
and ED-A fibronectin (Millipore) or β-actin (Cell Signal-
ing Technology). Blots were then incubated with appro-
priate HRP-conjugated mouse or rabbit secondary
antibodies. Protein bands were visualized using Western
Blotting Luminol Reagent (Santa Cruz Biotechnology)
on CL-Xposure blue X-ray film (Thermo Fisher
Scientific). Band intensities were quantified using Quan-
tity One (Bio-Rad) or ImageJ (National Institutes of
Health; NIH) applications. Target band intensity was
normalized to Gapdh, β-actin or α-tubulin.
Gelatin zymography
Serum-free conditioned cell culture medium from P1
proto-myofibroblasts was collected at 24 h or 48 h post-
infection with AdGFP or AdScx, and concentrated using
centrifugal filter devices (Millipore). Cardiac tissue ex-
tracts from WT and KO mice were prepared using lysis
buffer (25 mmol/L Tris-HCl pH 7.5, 100 mmol/L NaCl,
1 % NP-40) supplemented with protease inhibitors [53].
Next, 20 μg concentrated proteins (culture media or tis-
sue lysate) was electrophoresed under denaturing condi-
tions using commercial pre-cast 10 % acrylamide gels
containing 0.1 % gelatin (Novex, Life Technologies). Gels
were then renatured in 2.5 % Triton X-100 for 30 min at
room temperature followed by incubation in developing
buffer (50 mmol/L Tris base, 40 mmol/L HCl,
200 mmol/L NaCl, 5 mmol/L CaCl2 and 0.02 % Brij 35)
at 37 °C for 16 h in a closed tray. Gelatinolytic activity
was then visualized by staining with Coomassie Brilliant
Blue R-250 dye (0.5 % in 5 % methanol and 10 % acetic
acid) followed by destaining (10 % methanol, 5 % acetic
acid) to reveal clear bands over the blue background of
the dye. Gels were dried and scanned on a densitometer,
and band intensities were quantified using Image J soft-
ware (NIH) [54].
Flow cytometry
Whole hearts below the atria were isolated from WT
and scleraxis KO mice, and were immediately flushed
with ice-cold HBSS. The method described by Banerjee
et al. was used with modifications [55]. Briefly, hearts
were immersed in HBSS supplemented with 1 mg/mL
bovine serum albumin (BSA), minced and repeatedly
passed through a 19-gauge needle, then incubated for
5 min with shaking at 100 rpm at 37 °C. The super-
natant was collected, and the rest of the tissue was sub-
jected to enzymatic digestion using 140 U/mL
collagenase supplemented with 10 mg/mL BSA. This
process was repeated six times at 37 °C. The supernatant
was pooled from all steps and centrifuged at 1,000 × g
for 5 min at 4 °C. The supernatant was discarded and
cells resuspended in Gey’s solution for 5 min on ice to
lyse red blood cells. After centrifugation, cells were re-
suspended in 1 mL staining buffer (phosphate-buffered
saline with 1 % FBS). Cells were then counted and resus-
pended at 0.5 million cells/100 μL for flow cytometry
analysis. Cells were processed using the BD Cytofix/
Cytoperm kit (BD Biosciences) as per manufacturer’s in-
structions. Single-cell suspensions from both WT and
KO groups (n = 3) were stained with either FITC-
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conjugated-αSMA (Abcam), R-PE-conjugated-DDR2,
APC/Cy7-conjugated αMHC or PE/Cy7-conjugated-
CD31 (BD Biosciences) antibodies. Fluorochrome conju-
gation for DDR2 and αMHC was performed using Easy-
Link Kits (Abcam). Acquisition of cell samples was
performed on a FACSCanto II cytometer using FACS-
Diva software (BD Biosciences). Data were analyzed with
FlowJo software (Tree Star, Inc.).
Histology
Cardiac tissues from KO mice or WT littermates were
formaldehyde-fixed, embedded in OCT or paraffin and
processed for assessment of histological features. Next,
5 μm sections were subjected to Masson’s trichrome
staining using commercial reagents (Sigma-Aldrich).
Briefly, tissue sections were mordant in pre-heated
Bouin’s solution (Sigma-Aldrich) for 15 min at 56 °C,
then rinsed with tap water to remove excess reagent.
Sections were stained with Weigert’s hematoxylin solu-
tion (Sigma-Aldrich), rinsed sequentially in tap and de-
ionized water, and then stained with the trichrome kit.
Slides were treated with 1 % acetic acid, dehydrated
through alcohol, cleared in xylene and mounted using
Permount (Thermo Fisher Scientific). For discrete
visualization of collagen deposits in the myocardium, tis-
sue sections were stained with picrosirius red (PSR).
Slides were incubated in Bouin’s solution as above,
followed by staining in picrosirius red (0.1 %) for 60 min
at room temperature. Sections were then washed with
1 % acetic acid twice, dehydrated, cleared and mounted
using Permount. Both trichrome and PSR-stained sec-
tions were examined using a Zeiss Axioskop 2 mot plus
microscope equipped with an AxioCam digital camera,
40× Plan-Neofluar objective (NA 0.75) and AxioVision
4.6 software (Zeiss). Alternatively, PSR-stained sections
were visualized on an Axio Imager M1 microscope
equipped with a circular polarizer filter (Zeiss), AxioCam
HR digital camera and 40× objective as above. For en-
hanced visualization of blue staining in Masson’s tri-
chrome sections, images were processed with Adobe
Photoshop CS6 to remove the red and green color
channels.
Luciferase reporter assay
NIH-3T3 cells were plated in 6-well dishes and trans-
fected at ~70 % confluence. After equilibration in Opti-
MEM (Gibco) for 30 min, cells were co-transfected (Li-
pofectamine 2000, Life Technologies) with one of the
following luciferase reporter vectors: rat pGL3-αSMA
[56] (courtesy Dr Sem H. Phan, University of Michigan),
human pGL2-MMP2 [57] (courtesy Dr Etty Benveniste,
University of Alabama), human pGL3-vimentin [58, 59]
(courtesy Dr Christine Gilles, University of Liege) or hu-
man pGL3-fibronectin [60] (courtesy Dr Jesse Roman,
University of Louisville), and pECE (control) or scleraxis
expression vectors [6, 18] for 24 h. Renilla luciferase ex-
pression vector (pRL) was used for normalization of lu-
ciferase reporter activity. Luciferase activity in the
samples was analyzed using the Dual-Luciferase Re-
porter Assay System (Promega) on a Glomax-Multi +
Microplate Multimode Reader (Promega) equipped with
Instinct software. Point mutations were introduced in
the E-box sequences of the 0.7 kb αSMA promoter
construct using site-directed mutagenesis (Agilent
Technologies) (Additional file 2: Table S4) and veri-
fied by sequencing. A scleraxis double deletion mu-
tant (ScxΔΔ) was generated using nested PCR
(Additional file 2: Table S5).
Electrophoretic mobility shift assay
Gel mobility shift assays were performed as described
previously [18]. Biotin-labeled oligonucleotides and cold
probes (Additional file 2: Table S6) were synthesized
commercially (Integrated DNA Technologies). The as-
says were performed using a LightShift Chemilumines-
cent EMSA Kit (Pierce Biotechnology) according to
manufacturer’s instructions.
Chromatin immunoprecipitation (ChIP/re-ChIP) assay
Assays were performed as described previously [18]. Sol-
ubilized chromatin from adult rat cardiac fibroblasts and
myofibroblasts was incubated overnight at 4 °C with
10 μg anti-scleraxis antibody or pre-immune serum.
Protein-DNA complexes were isolated from scleraxis
WT and KO cardiac tissues using a commercial kit
(Millipore) and incubated with 5 μg anti-Smad3 antibody
(Abcam) or rabbit IgG (Santa Cruz Biotechnology) over-
night at 4 °C. For re-ChIP assays with anti-RNA Poly-
merase II Antibody (Millipore), after the elution of the
first ChIP assay, the samples were diluted ten times with
re-ChIP dilution buffer (15 mmol/L Tris-HCl pH 8.1,
1 % Triton X-100, 1 mmol/L EDTA, 150 mmol/L NaCl)
and subjected to the ChIP procedure again. Negative
controls included performing re-ChIP assays with mouse
IgG (Millipore). The immunoprecipitates were collected
and eluted DNA was subjected to qPCR using specific
primers (Integrated DNA Technologies; Additional file
2: Table S7) [61] and SYBR Green reagents (Quanta Bio-
sciences). Fold enrichment was calculated (ΔCt) and rep-
resents the ratio of protein-bound DNA (scleraxis,
Smad3 or RNA Pol II) to a negative control (pre-im-
mune serum or non-specific IgG) normalized for input
DNA. A region of Gapdh promoter (rat or mouse) was
amplified to represent negative control for the experi-
ments; no differences were observed for scleraxis or
Smad3-binding to the Gapdh promoter (P > 0.05; n = 3).
For experiments using dominant negative scleraxis mu-
tant, human cardiac myofibroblasts were infected with
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adenoviruses encoding the mutant (AdScxΔBD) or GFP
(AdGFP; control) at MOIs for 24 h followed by ChIP
and re-ChIP procedures as mentioned above.
Co-immunoprecipitation (Co-IP)
NIH-3T3 cells were transfected with the expression vec-
tors encoding scleraxis (pECE-HA-Scx), scleraxis
protein-binding domain mutant (pECE-HA-ScxΔHLH),
Smad3 (pCMV tag3C-Myc-Smad3; courtesy Dr Jean-
Jacques Lebrun, McGill University) or combinations
using Lipofectamine 3000 (Life Technologies) for 48 h.
Cells were then rinsed once with PBS and lysed in
50 mmol/L Tris (pH 7.5), 150 mmol/L NaCl and Triton
X-100 (0.5 %). Cell membranes were ruptured by passing
the lysate through a syringe with a 25-gauge needle.
Total protein was collected after centrifugation of lysates
at 14,000 rpm at 4 °C for 20 min. Protein complexes
(500 μg) were immunoprecipitated using an anti-HA
antibody (Rockland Immunochemicals Inc.) or rabbit
IgG (Santa Cruz Biotechnology), resolved on a 12 %
polyacrylamide gel followed by western blotting with an
anti-c-myc antibody (Developmental Studies Hybridoma
Bank). Whole-cell extracts were used for immunoblot-
ting with anti-HA or anti-c-myc antibody to confirm
transfection of expression vectors.
Immunofluorescence imaging
Cardiac P1 proto-myofibroblasts were plated onto glass
coverslips infected at MOI 10 with AdLacZ or AdScx
for 24 h. Cells were then fixed in 2 % paraformaldehyde
(Alfa Aesar), permeabilized in 0.3 % Triton X-100 and
0.1 % Na-citrate, and blocked in 5 % goat serum (Life
Technologies). Cells were incubated with FITC-αSMA
antibody (Abcam) at 4 °C overnight followed by mount-
ing onto slides using SlowFade Gold Antifade reagent
with DAPI (Molecular Probes, Thermo Fisher Scientific).
For DDR2, collagen I and Twist1 staining, paraffin-
embedded 5 μm tissue sections were deparaffinized and
rehydrated to distilled water. Tissue slides were proc-
essed for antigen retrieval using a citrate-based commer-
cial reagent (Vector Laboratories) at 90 °C for 30 min
and then cooled at room temperature for another
30 min. Sections were then washed with PBS and incu-
bated in blocking reagent (Roche Applied Science) for
1 h at room temperature. Slides were incubated with
antibodies against DDR2 (Sigma-Aldrich), collagen I
(Cedarlane) or Twist1 (Sigma-Aldrich) at 4 °C overnight.
Tissue sections were then washed three times with 0.1 %
Triton X-100 in PBS and incubated with Alexa Fluor
594-conjugated goat anti-rabbit secondary antibody (Life
Technologies) for 1 h at room temperature. Slides were
then rinsed in Triton/PBS and mounted with ProLong
Diamond Antifade Mountant (Life Technologies). Im-
ages were acquired using a Zeiss Axio Imager M1
epifluorescence microscope using appropriate filters and
a Plan-Apochromat 20× objective (NA 0.8) or a Plan-
Apochromat 63× objective (NA 1.40) with oil
immersion.
Gel contraction assay
Compressible collagen matrices were prepared as previ-
ously indicated [62]. Gels were prepared containing type I
collagen (Advanced BioMatrix) and 5 × DMEM, with pH
adjusted to 7.0–7.4. Cardiac proto-myofibroblasts sus-
pended in serum-supplemented DME/F-12 medium were
seeded (5 × 105 cells/well) on collagen gels for 24 h prior
to equilibration by serum deprivation and adenovirus in-
fection (AdGFP, AdScx, AdshLacZ or AdshScx at MOI
10). At initiation of contraction, gels were excised from
wells using a custom-fabricated stainless steel dowel or a
surgical blade (Thermo Fisher Scientific). Cells were
treated with 10 ng/mL recombinant human TGF-β1 (R&D
Systems) for 24 h. Well images were captured at 0 h and
24 h. Gel area for each well was determined using IDL
Measure Gel software and reported as percentage of max-
imal (10 % serum-induced) contraction [63].
Measurement of cardiomyocyte cross-sectional area
Cardiomyocyte cross-sectional area was measured as pre-
viously described [64, 65]. Six μm thick OCT-embedded
cardiac tissue sections were treated with 3.3 U/mL neur-
aminidase type V (Sigma-Aldrich) for 1 h at room
temperature. Sections were then rinsed with PBS and
stained with fluorescein-labelled peanut agglutinin (Vector
Laboratories) overnight at 4 °C. Tissue sections were
rinsed with PBS three times and mounted with ProLong
Diamond Antifade Mountant. The mountant was allowed
to cure overnight in the dark. Images were acquired on a
Zeiss Axio Imager M1 epifluorescence microscope with
an EC Plan-Neofluar 40× objective (NA 0.75), and
bounded area measured using AxioVision software. Fifty
cells were analyzed from each animal.
Determination of cardiac capillary density
Cardiac capillary density was assayed as previously de-
scribed [66, 67]. Six μm thick left ventricle sections were
treated with neuraminidase type V and stained with
Rhodamine-labeled Griffonia (Bandeiraea) simplicifolia
lectin I (GSL-I, BSL-I; Vector Laboratories) overnight at
4 °C. Slides were then washed with PBS, mounted using
ProLong Diamond Antifade Mountant and allowed to
cure overnight. Images were acquired as per measure-
ments of cardiomyocyte cross-sectional area. Two fields
were analyzed and averaged from each animal.
Statistical analysis
Results are reported as mean ± standard error for at least
three independent biological replicates for each sample;
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for studies involving animal tissue, each n represents
one individual animal for each genotype. Means were
compared by two-sided Student’s t-test, or for multiple
comparisons by one-way ANOVA with Student-
Newman-Keuls post-hoc analysis; results were consid-
ered significant when P < 0.05.
Availability of data and materials
Data supporting the results of this article are available in
Additional file 7.
Additional files
Additional file 1: Figure S1. A scleraxis double deletion mutant fails to
regulate target gene expression. (A) NIH-3T3 fibroblasts were transfected
with a human COL1A2 proximal promoter luciferase reporter vector, with
or without expression vectors for intact scleraxis (500 ng) or encoding a
scleraxis mutant lacking the DNA- and protein-binding domains (ScxΔΔ;
0–500 ng), plus a Renilla luciferase reporter (pRL) for normalization. After
24 h, cell lysates were collected for luciferase assay. Intact scleraxis
transactivated the COL1A2 promoter. In contrast, the ScxΔΔ mutant had
no effect either alone or with co-transfected intact scleraxis. Results were
normalized to control (C; reporter alone); mean ± SEM; n = 3; *P < 0.05 vs
control. (B, C) Primary cardiac proto-myofibroblasts were transfected by
electroporation with an expression vector encoding the scleraxis double
mutant (pScxΔΔ) or with control empty vector (pECE). Then, 24 h later,
mRNA expression of fibrillar collagen gene expression (B) or (myo)fibro-
blast markers (C) was assayed by qPCR. Results were normalized to the
control empty vector and Gapdh expression; mean ± SEM; n = 3; P > 0.05
for all comparisons (B–C). (EPS 1153 kb)
Additional file 2: Table S1. Echocardiographic parameters. Table S2.
Antibodies used in the study. Table S3. Primers used for qPCR analysis.
Table S4. Primers used for site-directed mutagenesis of αSMA proximal
promoter. Table S5. Primers used for nested PCR generation of ScxΔΔ.
Table S6. Probes used for electrophoretic mobility shift assay. Table S7.
Primers used for chromatin immunoprecipitation assay. (DOCX 34 kb)
Additional file 3: Figure S2. Flow cytometry analysis of cardiac cells
from WT and scleraxis KO mice. (A) Scatter profile shows cellular
aggregates and tissue debris being gated out using side-scatter area
(SSC-A) and forward-scatter area (FSC-A). (B) Forward-scatter plots for 5 ×
104 events labeled for αMHC, αSMA, DDR2 or CD31; left column, un-
stained cells; center column, stained cells from WT tissue; right column,
stained cells from scleraxis KO tissue. Results are representative of
assessments from n = 3 independent tissue samples. Purple outline
denotes labeled cells, and is derived from unstained plots. (EPS 7579 kb)
Additional file 4: Figure S3. Capillary density and cardiomyocyte
cross-sectional area analysis of cardiac sections from WT and scleraxis KO
mice. (A) Cardiac tissue sections (6 μm) from WT and scleraxis KO mice
were stained with Rhodamine-labeled GSL I and capillaries counted to
assess density. (B) Results for n = 3 independent samples per genotype
(two fields/sample); mean ± SEM; *P < 0.05 vs WT. (C) Cardiac tissue
sections (6 μm) from WT and scleraxis KO mice were stained with
fluorescein-labeled peanut agglutinin for measurement of cardiomyocyte
cross-sectional area. (D) Results for n = 3 independent samples per
genotype (50 cells/sample); mean ± SEM; *P < 0.05 vs WT; 40× objective,
scale bar = 25 μm. (EPS 19611 kb)
Additional file 5: Figure S4. LIVE/DEAD assay of primary cardiac
fibroblasts following scleraxis knockdown. (A) Primary adult rat cardiac
fibroblasts were assessed for viability by LIVE/DEAD assay following
treatment with AdshLacZ or AdshScx for 48 h. Viable cells are green,
while dead cells are red (arrowheads); 200 μM H2O2 was used as a
positive control for cell death. (B) Results from (A) were quantified and
reported as percent of dead cells out of total cells (789–1,660 cells
counted per biological replicate; 4–6 fields of cells were collectively
assessed for AdshLacZ and AdshScx samples; all cells died following H2O2
treatment; 417–541 cells counted per H2O2 replicate); mean ± SEM; n = 3;
P > 0.05 for AdshLacZ vs AdshScx; 10× objective, scale bar = 100 μm.
(EPS 16834 kb)
Additional file 6: Figure S5. Induction of fibroblast, mesenchyme and
tendon markers in C3H10T1/2 cells by scleraxis. C3H10T1/2 cells were
treated with AdGFP or AdScx for 48 h, and mRNA assayed by qPCR for
representative fibroblast, mesenchyme and tendon marker gene
expression. Results were normalized to Gapdh and AdGFP-infected
samples; mean ± SEM; n = 3; *P < 0.05 vs AdGFP. (EPS 978 kb)
Additional file 7: Supporting data. (XLSX 284 kb)
Abbreviations
αSMA: α-smooth muscle actin; DDR2: discoidin domain receptor 2;
ECM: extracellular matrix; EDA-Fn: extra domain-A splice variant of
fibronectin; EMT: epithelial-to-mesenchymal transition; FB: fibroblast;
KO: knockout; MFB: myofibroblast; MMP: matrix metalloproteinase;
pMFB: proto-myofibroblast; Scx: scleraxis; SMemb: embryonic smooth muscle
myosin; WT: wild type.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MPC conceived the study; experiments were performed by RAB, PR and NA;
reagents, vectors and animal models were generated by RA, LE, BA and RS;
data was analyzed by RAB, PR and MPC; the manuscript was written and
edited by RAB and MPC in consultation with RS. All authors read and
approved the final manuscript.
Acknowledgements
We thank Shreyas Devalapurkar, Ryan Wang, Viktoriya Mozolevska, Sari
Yakubovich, Sheena Bohonis and Drs Christine Zhang and Davinder Jassal for
technical assistance; Sunil Rattan, Morvarid Kavosh, Fahmida Jahan and Drs
Ian Dixon, Ryan Cunnington and Jeff Wigle for technical advice; and Dr Paul
Fernyhough for animal tissues. Luciferase reporter plasmids were kind gifts of
Drs Etty Benveniste (pGL2-MMP2), Christine Gilles (pGL3-vimentin), Sem Phan
(pGL3-αSMA) and Jesse Roman (pGL3-fibronectin). AdSmad3 was a gift of Dr
Ian Dixon. We thank Drs Andrew Halayko and Joe Gordon for providing
A549 and C3H10T1/2 cells, respectively. This work was supported by
Canadian Institutes of Health Research grant MOP-106671 (MPC) and a
generous donation from Mr John Loewen through the St. Boniface Hospital
Foundation. RAB received a doctoral research award from CIHR/Research
Manitoba. PR was supported by a studentship from Research Manitoba. The
authors declare no conflicts of interest.
Author details
1Institute of Cardiovascular Sciences, Boniface Hospital Albrechtsen Research
Centre and Department of Physiology and Pathophysiology, University of
Manitoba, R4008 St. Boniface Hospital Albrechtsen Research Centre, 351
Tache Avenue, Winnipeg, MB R2H 2A6, Canada. 2Shriners Hospital for
Children, Research Division and Department of Cell and Developmental
Biology, Oregon Health and Science University, Portland, OR 97239, USA.
Received: 5 January 2016 Accepted: 1 March 2016
References
1. Espira L, Czubryt MP. Emerging concepts in cardiac matrix biology. Can
J Physiol Pharmacol. 2009;87(12):996–1008.
2. Fan D, Takawale A, Lee J, Kassiri Z. Cardiac fibroblasts, fibrosis and
extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair.
2012;5(1):15.
3. Santiago JJ, Dangerfield AL, Rattan SG, Bathe KL, Cunnington RH, Raizman
JE, et al. Cardiac fibroblast to myofibroblast differentiation in vivo and
in vitro: expression of focal adhesion components in neonatal and adult rat
ventricular myofibroblasts. Dev Dyn. 2010;239(6):1573–84.
4. Dobaczewski M, de Haan JJ, Frangogiannis NG. The extracellular matrix
modulates fibroblast phenotype and function in the infarcted myocardium.
J Cardiovasc Transl Res. 2012;5(6):837–47.
Bagchi et al. BMC Biology  (2016) 14:21 Page 19 of 21
5. Wang J, Chen H, Seth A, McCulloch CA. Mechanical force regulation of
myofibroblast differentiation in cardiac fibroblasts. Am J Physiol Heart Circ
Physiol. 2003;285(5):H1871–81.
6. Espira L, Lamoureux L, Jones SC, Gerard RD, Dixon IM, Czubryt MP. The
basic helix-loop-helix transcription factor scleraxis regulates fibroblast
collagen synthesis. J Mol Cell Cardiol. 2009;47(2):188–95.
7. Sandbo N, Dulin N. Actin cytoskeleton in myofibroblast differentiation:
ultrastructure defining form and driving function. Transl Res. 2011;158(4):181–96.
8. Darby I, Skalli O, Gabbiani G. Alpha-smooth muscle actin is transiently
expressed by myofibroblasts during experimental wound healing. Lab
Invest. 1990;63(1):21–9.
9. Hinz B, Celetta G, Tomasek JJ, Gabbiani G, Chaponnier C. Alpha-smooth
muscle actin expression upregulates fibroblast contractile activity. Mol Biol
Cell. 2001;12(9):2730–41.
10. Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, et al. The
fibronectin domain ED-A is crucial for myofibroblastic phenotype induction
by transforming growth factor-beta1. J Cell Biol. 1998;142(3):873–81.
11. Frangogiannis NG, Michael LH, Entman ML. Myofibroblasts in reperfused
myocardial infarcts express the embryonic form of smooth muscle myosin
heavy chain (SMemb). Cardiovasc Res. 2000;48(1):89–100.
12. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts
and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell
Biol. 2002;3(5):349–63.
13. Desmouliere A, Chaponnier C, Gabbiani G. Tissue repair, contraction, and
the myofibroblast. Wound Repair Regen. 2005;13(1):7–12.
14. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The
myofibroblast: one function, multiple origins. Am J Pathol. 2007;170(6):1807–16.
15. Levay AK, Peacock JD, Lu Y, Koch M, Hinton Jr RB, Kadler KE, et al. Scleraxis
is required for cell lineage differentiation and extracellular matrix
remodeling during murine heart valve formation in vivo. Circ Res. 2008;
103(9):948–56.
16. Hinz B. Formation and function of the myofibroblast during tissue repair.
J Invest Dermatol. 2007;127(3):526–37.
17. Murchison ND, Price BA, Conner DA, Keene DR, Olson EN, Tabin CJ, et al.
Regulation of tendon differentiation by scleraxis distinguishes force-
transmitting tendons from muscle-anchoring tendons. Development.
2007;134(14):2697–708.
18. Bagchi RA, Czubryt MP. Synergistic roles of scleraxis and Smads in the
regulation of collagen 1alpha2 gene expression. Biochim Biophys Acta.
2012;1823(10):1936–44.
19. Lejard V, Brideau G, Blais F, Salingcarnboriboon R, Wagner G, Roehrl MH,
et al. Scleraxis and NFATc regulate the expression of the pro-alpha1(I)
collagen gene in tendon fibroblasts. J Biol Chem. 2007;282(24):17665–75.
20. Barnette DN, Hulin A, Ahmed AS, Colige AC, Azhar M, Lincoln J. Tgfbeta-
Smad and MAPK signaling mediate scleraxis and proteoglycan expression in
heart valves. J Mol Cell Cardiol. 2013;65:137–46.
21. Burgess R, Cserjesi P, Ligon KL, Olson EN. Paraxis: a basic helix-loop-helix
protein expressed in paraxial mesoderm and developing somites. Dev Biol.
1995;168(2):296–306.
22. Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA, et al.
Periostin promotes fibrosis and predicts progression in patients with
idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012;
303(12):L1046–56.
23. Snider P, Standley KN, Wang J, Azhar M, Doetschman T, Conway SJ. Origin
of cardiac fibroblasts and the role of periostin. Circ Res. 2009;105(10):934–47.
24. Blank RS, McQuinn TC, Yin KC, Thompson MM, Takeyasu K, Schwartz RJ, et
al. Elements of the smooth muscle alpha-actin promoter required in cis for
transcriptional activation in smooth muscle. Evidence for cell type-specific
regulation. J Biol Chem. 1992;267(2):984–9.
25. Jung F, Johnson AD, Kumar MS, Wei B, Hautmann M, Owens GK, et al.
Characterization of an E-box-dependent cis element in the smooth muscle
alpha-actin promoter. Arterioscler Thromb Vasc Biol. 1999;19(11):2591–9.
26. Abe H, Tominaga T, Matsubara T, Abe N, Kishi S, Nagai K, et al. Scleraxis
modulates bone morphogenetic protein 4 (BMP4)-Smad1 protein-smooth
muscle alpha-actin (SMA) signal transduction in diabetic nephropathy. J Biol
Chem. 2012;287(24):20430–42.
27. Berthet E, Chen C, Butcher K, Schneider RA, Alliston T, Amirtharajah M.
Smad3 binds scleraxis and mohawk and regulates tendon matrix
organization. J Orthop Res. 2013;31(9):1475–83.
28. Goldsmith EC, Hoffman A, Morales MO, Potts JD, Price RL, McFadden A,
et al. Organization of fibroblasts in the heart. Dev Dyn. 2004;230(4):787–94.
29. Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of
cardiac fibroblasts. Cardiovasc Res. 2005;65(1):40–51.
30. Ieda M, Tsuchihashi T, Ivey KN, Ross RS, Hong TT, Shaw RM, et al. Cardiac
fibroblasts regulate myocardial proliferation through beta1 integrin
signaling. Dev Cell. 2009;16(2):233–44.
31. Acharya A, Baek ST, Huang G, Eskiocak B, Goetsch S, Sung CY, et al. The
bHLH transcription factor Tcf21 is required for lineage-specific EMT of
cardiac fibroblast progenitors. Development. 2012;139(12):2139–49.
32. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition.
J Clin Invest. 2009;119(6):1420–8.
33. Li Y, Ramcharan M, Zhou Z, Leong DJ, Akinbiyi T, Majeska RJ, et al. The role
of scleraxis in fate determination of mesenchymal stem cells for tenocyte
differentiation. Scientific Reports. 2015;5:13149.
34. Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z. TGF-beta1 induces
human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res.
2005;6:56.
35. Shukunami C, Takimoto A, Oro M, Hiraki Y. Scleraxis positively regulates the
expression of tenomodulin, a differentiation marker of tenocytes. Dev Biol.
2006;298(1):234–47.
36. Chen X, Yin Z, Chen JL, Shen WL, Liu HH, Tang QM, et al. Force and
scleraxis synergistically promote the commitment of human ES cells derived
MSCs to tenocytes. Scientific Reports. 2012;2:977.
37. Chen W, Tang H, Zhou M, Hu C, Zhang J, Tang K. Dexamethasone inhibits
the differentiation of rat tendon stem cells into tenocytes by targeting the
scleraxis gene. J Steroid Biochem Mol Biol. 2015;152:16–24.
38. Roberts AB, Tian F, Byfield SD, Stuelten C, Ooshima A, Saika S, et al. Smad3
is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis,
tumor suppression and metastasis. Cytokine Growth Factor Rev. 2006;17(1-
2):19–27.
39. Cserjesi P, Brown D, Ligon KL, Lyons GE, Copeland NG, Gilbert DJ, et al.
Scleraxis: a basic helix-loop-helix protein that prefigures skeletal formation
during mouse embryogenesis. Development. 1995;121(4):1099–110.
40. Katz TC, Singh MK, Degenhardt K, Rivera-Feliciano J, Johnson RL, Epstein JA,
et al. Distinct compartments of the proepicardial organ give rise to
coronary vascular endothelial cells. Dev Cell. 2012;22(3):639–50.
41. Bhandari RK, Schinke EN, Haque MM, Sadler-Riggleman I, Skinner MK. SRY
induced TCF21 genome-wide targets and cascade of bHLH factors during
Sertoli cell differentiation and male sex determination in rats. Biol Reprod.
2012;87(6):131.
42. Klingberg F, Hinz B, White ES. The myofibroblast matrix: implications for
tissue repair and fibrosis. J Pathol. 2013;229(2):298–309.
43. Ladage D, Yaniz-Galende E, Rapti K, Ishikawa K, Tilemann L, Shapiro S, et al.
Stimulating myocardial regeneration with periostin Peptide in large
mammals improves function post-myocardial infarction but increases
myocardial fibrosis. PLoS One. 2013;8(5):e59656.
44. Oka T, Xu J, Kaiser RA, Melendez J, Hambleton M, Sargent MA, et al. Genetic
manipulation of periostin expression reveals a role in cardiac hypertrophy
and ventricular remodeling. Circ Res. 2007;101(3):313–21.
45. Roche PL, Filomeno KL, Bagchi RA, Czubryt MP. Intracellular signaling of
cardiac fibroblasts. Comprehensive Physiology. 2015;5(2):721–60.
46. Jassal DS, Han SY, Hans C, Sharma A, Fang T, Ahmadie R, et al. Utility of
tissue Doppler and strain rate imaging in the early detection of trastuzumab
and anthracycline mediated cardiomyopathy. J Am Soc Echocardiogr. 2009;
22(4):418–24.
47. Walker JR, Sharma A, Lytwyn M, Bohonis S, Thliveris J, Singal PK, et al. The
cardioprotective role of probucol against anthracycline and trastuzumab-
mediated cardiotoxicity. J Am Soc Echocardiogr. 2011;24(6):699–705.
48. Rossi MA. Fibrosis and inflammatory cells in human chronic chagasic
myocarditis: scanning electron microscopy and immunohistochemical
observations. Int J Cardiol. 1998;66(2):183–94.
49. Rossi MA, Abreu MA, Santoro LB. Images in cardiovascular medicine.
Connective tissue skeleton of the human heart: a demonstration by cell-
maceration scanning electron microscope method. Circulation.
1998;97(9):934–5.
50. Raizman JE, Komljenovic J, Chang R, Deng C, Bedosky KM, Rattan SG, et al.
The participation of the Na + -Ca2+ exchanger in primary cardiac
myofibroblast migration, contraction, and proliferation. J Cell Physiol.
2007;213(2):540–51.
51. Haudek SB, Xia Y, Huebener P, Lee JM, Carlson S, Crawford JR, et al. Bone
marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in
mice. Proc Natl Acad Sci U S A. 2006;103(48):18284–9.
Bagchi et al. BMC Biology  (2016) 14:21 Page 20 of 21
52. Abrenica B, AlShaaban M, Czubryt MP. The A-kinase anchor protein
AKAP121 is a negative regulator of cardiomyocyte hypertrophy. J Mol Cell
Cardiol. 2009;46(5):674–81.
53. Toth M, Sohail A, Fridman R. Assessment of gelatinases (MMP-2 and MMP-9)
by gelatin zymography. Methods Mol Biol. 2012;878:121–35.
54. Hu X, Beeton C. Detection of functional matrix metalloproteinases by
zymography. J Vis Exp. 2010;8(45):2445.
55. Banerjee I, Fuseler JW, Price RL, Borg TK, Baudino TA. Determination of cell
types and numbers during cardiac development in the neonatal and adult
rat and mouse. Am J Physiol Heart Circ Physiol. 2007;293(3):H1883–91.
56. Hu B, Wu Z, Phan SH. Smad3 mediates transforming growth factor-beta-
induced alpha-smooth muscle actin expression. Am J Respir Cell Mol Biol.
2003;29(3 Pt 1):397–404.
57. Qin H, Sun Y, Benveniste EN. The transcription factors Sp1, Sp3, and AP-2
are required for constitutive matrix metalloproteinase-2 gene expression in
astroglioma cells. J Biol Chem. 1999;274(41):29130–7.
58. Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P,
et al. Transactivation of vimentin by beta-catenin in human breast cancer
cells. Cancer Res. 2003;63(10):2658–64.
59. Bindels S, Mestdagt M, Vandewalle C, Jacobs N, Volders L, Noel A, et al.
Regulation of vimentin by SIP1 in human epithelial breast tumor cells.
Oncogene. 2006;25(36):4975–85.
60. Michaelson JE, Ritzenthaler JD, Roman J. Regulation of serum-induced
fibronectin expression by protein kinases, cytoskeletal integrity, and CREB.
Am J Physiol Lung Cell Mol Physiol. 2002;282(2):L291–301.
61. Kalita K, Kharebava G, Zheng JJ, Hetman M. Role of megakaryoblastic acute
leukemia-1 in ERK1/2-dependent stimulation of serum response factor-
driven transcription by BDNF or increased synaptic activity. J Neurosci. 2006;
26(39):10020–32.
62. Drobic V, Cunnington RH, Bedosky KM, Raizman JE, Elimban VV, Rattan SG,
et al. Differential and combined effects of cardiotrophin-1 and TGF-beta1
on cardiac myofibroblast proliferation and contraction. Am J Physiol Heart
Circ Physiol. 2007;293(2):H1053–64.
63. Cunnington RH, Wang B, Ghavami S, Bathe KL, Rattan SG, Dixon IM.
Antifibrotic properties of c-Ski and its regulation of cardiac myofibroblast
phenotype and contractility. Am J Physiol Cell Physiol. 2011;300(1):C176–86.
64. Liu YH, Xu J, Yang XP, Yang F, Shesely E, Carretero OA. Effect of ACE
inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO
synthase knockout mice with heart failure. Hypertension. 2002;39(2 Pt 2):
375–81.
65. Spiltoir JI, Stratton MS, Cavasin MA, Demos-Davies K, Reid BG, Qi J, et al. BET
acetyl-lysine binding proteins control pathological cardiac hypertrophy.
J Mol Cell Cardiol. 2013;63:175–9.
66. Harding P, Yang XP, He Q, Lapointe MC. Lack of microsomal prostaglandin
E synthase-1 reduces cardiac function following angiotensin II infusion. Am
J Physiol Heart Circ Physiol. 2011;300(3):H1053–61.
67. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K. Vascular
endothelial growth factor blockade promotes the transition from
compensatory cardiac hypertrophy to failure in response to pressure
overload. Hypertension. 2006;47(5):887–93.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Bagchi et al. BMC Biology  (2016) 14:21 Page 21 of 21
